BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nault J, Sutter O, Nahon P, Ganne-carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. Journal of Hepatology 2018;68:783-97. [DOI: 10.1016/j.jhep.2017.10.004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 100] [Article Influence: 24.8] [Reference Citation Analysis]
Number Citing Articles
1 Shen YC, Hsu HC, Lin TM, Chang YS, Hu LF, Chen LF, Lin SH, Kuo PI, Chen WS, Lin YC, Chen JH, Liang YC, Chang CC. H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection. J Clin Oncol 2022;:JCO2101802. [PMID: 35044851 DOI: 10.1200/JCO.21.01802] [Reference Citation Analysis]
2 Gaia S, Ciruolo M, Ribaldone DG, Rolle E, Migliore E, Mosso E, Vola S, Risso A, Fagoonee S, Saracco GM, Carucci P. Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma. Curr Oncol 2021;28:1034-44. [PMID: 33669107 DOI: 10.3390/curroncol28020101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yan L, Chen L, Qian K, Kan X, Zhang H, Liang B, Zheng C. Caudate Lobe Hepatocellular Carcinoma Treated with Sequential Transarterial Chemoembolization and Iodine 125 Seeds Implantation: A Single-Center Retrospective Study. Cancer Manag Res 2021;13:3901-12. [PMID: 34012296 DOI: 10.2147/CMAR.S309310] [Reference Citation Analysis]
4 Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study. BMC Gastroenterol 2021;21:182. [PMID: 33879085 DOI: 10.1186/s12876-021-01765-x] [Reference Citation Analysis]
5 Hendriquez R, Keihanian T, Goyal J, Abraham RR, Mishra R, Girotra M. Radiofrequency ablation in the management of primary hepatic and biliary tumors. World J Gastrointest Oncol 2022; 14(1): 203-215 [DOI: 10.4251/wjgo.v14.i1.203] [Reference Citation Analysis]
6 Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Reference Citation Analysis]
7 Bockorny B, Bullock AJ, Abrams TA, Faintuch S, Alsop DC, Goldberg SN, Ahmed M, Miksad RA. Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma. Dig Dis Sci 2021. [PMID: 34297268 DOI: 10.1007/s10620-021-07156-2] [Reference Citation Analysis]
8 Guiu B, De Baère T, Noel G, Ronot M. Feasibility, safety and accuracy of a CT-guided robotic assistance for percutaneous needle placement in a swine liver model. Sci Rep 2021;11:5218. [PMID: 33664412 DOI: 10.1038/s41598-021-84878-3] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Tian Z, Hong B, Chen J, Tang Z. Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis. Front Oncol 2022;12:891724. [PMID: 35719978 DOI: 10.3389/fonc.2022.891724] [Reference Citation Analysis]
10 Hu J, Pei W, Jiang Z, Li Z. A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation. Cancer Nano 2021;12. [DOI: 10.1186/s12645-021-00105-8] [Reference Citation Analysis]
11 Yamamoto M, Kobayashi T, Honmyo N, Oshita A, Abe T, Kohashi T, Onoe T, Fukuda S, Omori I, Imaoka Y, Ohdan H. Liver resection is associated with good outcomes for hepatocellular carcinoma patients beyond the Barcelona Clinic Liver Cancer criteria: A multicenter study with the Hiroshima Surgical study group of Clinical Oncology. Surgery 2021:S0039-6060(21)00891-6. [PMID: 34756748 DOI: 10.1016/j.surg.2021.09.009] [Reference Citation Analysis]
12 Liu ZG, Chen XH, Yu ZJ, Lv J, Ren ZG. Recent progress in pulsed electric field ablation for liver cancer. World J Gastroenterol 2020; 26(24): 3421-3431 [PMID: 32655266 DOI: 10.3748/wjg.v26.i24.3421] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Du S, Yang JZ, Chen J, Zhou WG, Sun YY. Comparisons of recurrence-free survival and overall survival between microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A multiple centers retrospective cohort study with propensity score matching. PLoS One 2020;15:e0227242. [PMID: 31918433 DOI: 10.1371/journal.pone.0227242] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Chen P, Chiu N, Su C, Huang Y, Hou M, Lin H, Wu J. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association 2019;82:2-10. [DOI: 10.1097/jcma.0000000000000001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
15 Inzerillo A, Meloni MF, Taibbi A, Bartolotta TV. Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography. World J Hepatol 2022; 14(5): 911-922 [DOI: 10.4254/wjh.v14.i5.911] [Reference Citation Analysis]
16 Hayashi K, Tokuda A, Nakamura J, Sugawara-Narutaki A, Ohtsuki C. Tearable and Fillable Composite Sponges Capable of Heat Generation and Drug Release in Response to Alternating Magnetic Field. Materials (Basel) 2020;13:E3637. [PMID: 32824485 DOI: 10.3390/ma13163637] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 66.0] [Reference Citation Analysis]
18 Wei J, Cui W, Fan W, Wang Y, Li J. Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation. Front Oncol 2020;10:1285. [PMID: 32850395 DOI: 10.3389/fonc.2020.01285] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen L, Ren Y, Sun T, Cao Y, Yan L, Zhang W, Ouyang T, Zheng C. The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study. Cancer Med 2021;10:3715-25. [PMID: 33960697 DOI: 10.1002/cam4.3923] [Reference Citation Analysis]
20 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
21 Schullian P, Johnston E, Laimer G, Scharll Y, Putzer D, Eberle G, Kolbitsch C, Amann A, Stättner S, Bale R. Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence. HPB (Oxford) 2021:S1365-182X(21)01705-6. [PMID: 34887174 DOI: 10.1016/j.hpb.2021.11.010] [Reference Citation Analysis]
22 Shao SY, Hu QD, Wang M, Zhao XY, Wu WT, Huang JM, Liang TB. Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018. World J Gastroenterol 2019; 25(32): 4749-4763 [PMID: 31528099 DOI: 10.3748/wjg.v25.i32.4749] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Li JP, Zhao S, Jiang HJ, Jiang H, Zhang LH, Shi ZX, Fan TT, Wang S. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00135-7. [PMID: 35729000 DOI: 10.1016/j.hbpd.2022.06.003] [Reference Citation Analysis]
24 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 82.0] [Reference Citation Analysis]
25 Yamamoto T, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, Matsushita T, Ishigami M, Fujishiro M. Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma patients with haemophilia. Haemophilia 2021;27:100-7. [PMID: 33245832 DOI: 10.1111/hae.14220] [Reference Citation Analysis]
26 Kim R, Kang TW, Cha DI, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications. Eur Radiol. 2018; Epub ahead of print. [PMID: 30043160 DOI: 10.1007/s00330-018-5617-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
27 Nguyen N, Rode A, Trillaud H, Aubé C, Manichon AF, Hocquelet A, Paisant A, Dao T, Nahon P, Ganne-Carrié N, Blaise L, Cauchy F, Sutter O, Séror O, Nault JC. Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease. Liver Int 2021. [PMID: 34894060 DOI: 10.1111/liv.15129] [Reference Citation Analysis]
28 Tian X, Lian J, Li X, Chen X, Yuan H, Zhou M, Liu F. Intra-arterial delivery of doxorubicin-loaded hollow gold nanospheres—photothermal ablation and chemoembolisation therapy in a rabbit VX2 liver cancer model. Journal of Experimental Nanoscience 2022;17:439-50. [DOI: 10.1080/17458080.2022.2091132] [Reference Citation Analysis]
29 de Jong KP, Ruiter SJS, Pennings JP. Stereotactic image guided microwave ablation of HCC: A step forward and still a long way to go. Liver Int 2019;39:1798-800. [PMID: 31553528 DOI: 10.1111/liv.14238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Fan R, Bian M, Hu L, Liu W. A new rhodium(I) NHC complex inhibits TrxR: In vitro cytotoxicity and in vivo hepatocellular carcinoma suppression. Eur J Med Chem 2019;183:111721. [PMID: 31577978 DOI: 10.1016/j.ejmech.2019.111721] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
31 Cao Y, Zhou Y, Pan J, Zhong X, Ding J, Jing X, Sun S. A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy. Chemical Engineering Journal 2021;422:130111. [DOI: 10.1016/j.cej.2021.130111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
32 Cillo U, Bertacco A, Fasolo E, Carandina R, Vitale A, Zanus G, Gringeri E, D'Amico F, Bassi D, Neri D, Dadduzio V, Farinati F, Aliberti C. Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures. J Surg Oncol 2019;120:956-65. [PMID: 31373009 DOI: 10.1002/jso.25651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
33 Zhu F, Wang BR, Zhu ZF, Wang SQ, Chai CX, Shang D, Li M. Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma? World J Gastrointest Surg 2021; 13(12): 1523-1535 [DOI: 10.4240/wjgs.v13.i12.1523] [Reference Citation Analysis]
34 Lei H, Wang G, Zhang J, Han Q. Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity. Oncol Rep 2018;40:3447-57. [PMID: 30272318 DOI: 10.3892/or.2018.6740] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
35 Jia H, Gao Z, Yu F, Guo H, Li B. Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice. Exp Ther Med 2021;21:454. [PMID: 33747188 DOI: 10.3892/etm.2021.9885] [Reference Citation Analysis]
36 Lu Y, Lu C, Xu D, Huang F, He Z, Lei J, Sun H, Zeng J. Computed Tomography-Guided Percutaneous Radiofrequency Ablation in Older Adults With Early-Stage Peripheral Lung Cancer: A Retrospective Cohort Study. Cancer Control 2022;29:107327482110707. [DOI: 10.1177/10732748211070702] [Reference Citation Analysis]
37 Lee MW, Kang D, Lim HK, Cho J, Sinn DH, Kang TW, Song KD, Rhim H, Cha DI, Lu DSK. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 2020;30:2391-400. [DOI: 10.1007/s00330-019-06575-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
38 Chen PY, Tsai TJ, Yang HY, Chou CK, Chang LJ, Chen TH, Hsu MT, Fang CC, Su CC, Lin YL, Feng YM, Chen CY. The Incidence of Bacteremia and Risk Factors of Post-Radiofrequency Ablation Fever for Patients with Hepato-Cellular Carcinoma. Cancers (Basel) 2021;13:5303. [PMID: 34771466 DOI: 10.3390/cancers13215303] [Reference Citation Analysis]
39 Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Song T, Wang C, Guo C, Liu Q, Zheng X. Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J Cancer 2018;9:2650-8. [PMID: 30087705 DOI: 10.7150/jca.25188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
41 Radosevic A, Quesada R, Serlavos C, Sánchez J, Zugazaga A, Sierra A, Coll S, Busto M, Aguilar G, Flores D, Arce J, Maiques JM, Garcia-Retortillo M, Carrion JA, Visa L, Villamonte M, Pueyo E, Berjano E, Trujillo M, Sánchez-Velázquez P, Grande L, Burdio F. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. Sci Rep 2022;12:316. [PMID: 35013377 DOI: 10.1038/s41598-021-03802-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Putzer D, Schullian P, Braunwarth E, Fodor M, Primavesi F, Cardini B, Resch T, Oberhuber R, Maglione M, Margreiter C, Schneeberger S, Stättner S, Öfner-Velano D, Jaschke W, Bale RJ. Integrating interventional oncology in the treatment of liver tumors. Eur Surg 2018;50:117-24. [PMID: 29875800 DOI: 10.1007/s10353-018-0521-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
43 Chen H, Jia W. Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes Dis 2020;7:320-7. [PMID: 32884986 DOI: 10.1016/j.gendis.2020.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Zeng P, Shen D, Zeng CH, Chang XF, Teng GJ. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Curr Oncol Rep 2020;22:76. [PMID: 32596779 DOI: 10.1007/s11912-020-00943-6] [Reference Citation Analysis]
45 Li FY, Li JG, Wu SS, Ye HL, He XQ, Zeng QJ, Zheng RQ, An C, Li K. An Optimal Ablative Margin of Small Single Hepatocellular Carcinoma Treated with Image-Guided Percutaneous Thermal Ablation and Local Recurrence Prediction Base on the Ablative Margin: A Multicenter Study. J Hepatocell Carcinoma 2021;8:1375-88. [PMID: 34815974 DOI: 10.2147/JHC.S330746] [Reference Citation Analysis]
46 Radosevic A, Prieto D, Burdío F, Berjano E, Prakash P, Trujillo M. Short pulsed microwave ablation: computer modeling and ex vivo experiments. Int J Hyperthermia 2021;38:409-20. [PMID: 33719808 DOI: 10.1080/02656736.2021.1894358] [Reference Citation Analysis]
47 Jiang YQ, Wang ZX, Deng YN, Yang Y, Wang GY, Chen GH. Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size. Front Oncol. 2019;9:113. [PMID: 30863723 DOI: 10.3389/fonc.2019.00113] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
48 Shui Y, Zhu X, Wu J, Liang T, Wei Q. Stereotactic body radiotherapy as the initial treatment for hepatocellular carcinoma with extensive inferior vena cava and atrium tumor thrombus. Onco Targets Ther 2019;12:5299-303. [PMID: 31308700 DOI: 10.2147/OTT.S208560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Yang Y, Chen Y, Zhang X, Xin Y, Wang Y, Li X, Fan Q, Zhou X, Ye F. Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: A multicenter retrospective study. Eur J Radiol 2021;138:109623. [PMID: 33711573 DOI: 10.1016/j.ejrad.2021.109623] [Reference Citation Analysis]
50 Bitterman DS, Cagney DN, Singer LL, Nguyen PL, Catalano PJ, Mak RH. Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. J Natl Cancer Inst 2020;112:229-37. [PMID: 31504680 DOI: 10.1093/jnci/djz167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
51 Pedersoli F, Ritter A, Zimmermann M, Schulze-hagen M, Liebl M, Dethlefsen E, von Stillfried S, Pfeffer J, Kuhl CK, Bruners P, Isfort P. Single-needle electroporation and interstitial electrochemotherapy: in vivo safety and efficacy evaluation of a new system. Eur Radiol 2019;29:6300-8. [DOI: 10.1007/s00330-019-06251-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
52 Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Schoenberg SO, Attenberger UI, Solomon SB, Weissleder R. Developing a Roadmap for Interventional Oncology. Oncologist 2018;23:1162-70. [PMID: 29959284 DOI: 10.1634/theoncologist.2017-0654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
54 Xue J, Ni H, Wang F, Xu K, Niu M. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. J Interv Med 2021;4:105-13. [PMID: 34805958 DOI: 10.1016/j.jimed.2021.05.002] [Reference Citation Analysis]
55 Nault JC, Nahon P, Séror O. Percutaneous ablation for HCC eligible to transplantation: providing more opportunities of remission in the context of graft shortage. Hepatobiliary Surg Nutr 2018;7:302-4. [PMID: 30221161 DOI: 10.21037/hbsn.2018.06.01] [Reference Citation Analysis]
56 Peng Z, Ouyang X, Wang Y, Fan Q. MAPKAPK5-AS1 drives the progression of hepatocellular carcinoma via regulating miR-429/ZEB1 axis. BMC Mol Cell Biol 2022;23:21. [PMID: 35468721 DOI: 10.1186/s12860-022-00420-x] [Reference Citation Analysis]
57 Dhar J, Samanta J. Role of endoscopic ultrasound in the field of hepatology: Recent advances and future trends. World J Hepatol 2021; 13(11): 1459-1483 [PMID: 34904024 DOI: 10.4254/wjh.v13.i11.1459] [Reference Citation Analysis]
58 Yang Y, Chen Y, Ye F, Cao X, Xin Y, Wang Y, Lei Y, Li X, Feng D, Zhou X, Fan Q. Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Eur Radiol 2021;31:3053-64. [PMID: 33175203 DOI: 10.1007/s00330-020-07460-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
59 Yang Y, Xin Y, Ye F, Liu N, Zhang X, Wang Y, Li X, Fan Q, Zhou X, Chen Y. Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors. Int J Hyperthermia 2021;38:437-46. [PMID: 33724137 DOI: 10.1080/02656736.2020.1849828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kang TW, Lim HK, Cha DI. Percutaneous ablation for perivascular hepatocellular carcinoma: Refining the current status based on emerging evidence and future perspectives. World J Gastroenterol 2018; 24(47): 5331-5337 [PMID: 30598578 DOI: 10.3748/wjg.v24.i47.5331] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
61 Green BL, House MG. Nonsurgical Approaches to Treat Biliary Tract and Liver Tumors. Surg Oncol Clin N Am 2019;28:573-86. [PMID: 31472906 DOI: 10.1016/j.soc.2019.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Hendriks P, Berkhout WEM, Kaanen CI, Sluijter JH, Visser IJ, van den Dobbelsteen JJ, de Geus-Oei LF, Webb AG, Burgmans MC. Performance of the Emprint and Amica Microwave Ablation Systems in ex vivo Porcine Livers: Sphericity and Reproducibility Versus Size. Cardiovasc Intervent Radiol 2021;44:952-8. [PMID: 33462682 DOI: 10.1007/s00270-020-02742-9] [Reference Citation Analysis]
63 Nahon P, Vibert E, Nault JC, Ganne-Carrié N, Ziol M, Seror O. Optimizing curative management of hepatocellular carcinoma. Liver Int 2020;40 Suppl 1:109-15. [PMID: 32077602 DOI: 10.1111/liv.14345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
64 Lin CC, Lui KW, Chen WT, Hsieh YC, Cheng YT, Teng W, Lin SM. Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma. Eur Radiol 2021. [PMID: 33895858 DOI: 10.1007/s00330-021-07729-9] [Reference Citation Analysis]
65 Cha SY, Kang TW, Min JH, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH, Park MS. RF Ablation Versus Cryoablation for Small Perivascular Hepatocellular Carcinoma: Propensity Score Analyses of Mid-Term Outcomes. Cardiovasc Intervent Radiol 2020;43:434-44. [PMID: 31844951 DOI: 10.1007/s00270-019-02394-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
66 Ramtohul T, Vilgrain V, Soubrane O, Bouattour M, Luciani A, Kobeiter H, Mule S, Tacher V, Laurent A, Amaddeo G, Regnault H, Bulsei J, Nault J, Nahon P, Durand-zaleski I, Seror O. Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers 2022;14:2634. [DOI: 10.3390/cancers14112634] [Reference Citation Analysis]
67 Ho P, Teng W, Lin C, Jeng W, Chen W, Lin C, Lin S, Sheen I. Prolonged post-ablation fever may predict one-year tumor recurrence in hepatocellular carcinoma after radiofrequency ablation. International Journal of Hyperthermia 2020;37:1008-15. [DOI: 10.1080/02656736.2020.1806363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Hong J, Cao L, Xie H, Liu Y, Yu J, Zheng S. Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis. Hepatobiliary Surg Nutr 2021;10:623-30. [PMID: 34760966 DOI: 10.21037/hbsn.2020.03.15] [Reference Citation Analysis]
69 Li L, Guo X, Peng X, Zhang H, Liu Y, Li H, He X, Shi D, Xiong B, Zhao Y, Zheng C, Yang X. Radiofrequency-responsive dual-valent gold nanoclusters for enhancing synergistic therapy of tumor ablation and artery embolization. Nano Today 2020;35:100934. [DOI: 10.1016/j.nantod.2020.100934] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
70 Yan X, Zhuang LP, Ning ZY, Wang P, Meng ZQ. Addition of thermal ablation to systemic chemotherapy for the treatment of unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis. Expert Rev Gastroenterol Hepatol 2021;:1-8. [PMID: 34937481 DOI: 10.1080/17474124.2022.2021067] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Zhou ZF, Peng F, Li JY, Ye YB. Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model. Onco Targets Ther 2019;12:7773-84. [PMID: 31571927 DOI: 10.2147/OTT.S222097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Wang L, Ke Q, Huang Q, Shao L, Chen J, Wu J. Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. International Journal of Hyperthermia 2020;37:1313-21. [DOI: 10.1080/02656736.2020.1843719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
73 Yang Y, Yu H, Qi L, Liu C, Feng Y, Qi J, Li J, Zhu Q. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis. Int J Hyperthermia 2022;39:455-65. [PMID: 35271786 DOI: 10.1080/02656736.2022.2048095] [Reference Citation Analysis]
74 Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C. Superselective Transarterial Chemoembolization for Unresectable or "Ablation Unsuitable" Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study. Front Oncol 2021;11:678847. [PMID: 34778023 DOI: 10.3389/fonc.2021.678847] [Reference Citation Analysis]
75 Yun BY, Lee HW, Min IK, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. Cancers (Basel). 2020;12. [PMID: 32899584 DOI: 10.3390/cancers12092527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Funaoka A, Numata K, Takeda A, Saigusa Y, Tsurugai Y, Nihonmatsu H, Chuma M, Fukuda H, Okada M, Nakano M, Maeda S. Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma. Diagnostics (Basel) 2021;11:486. [PMID: 33803373 DOI: 10.3390/diagnostics11030486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Lee S, Kang TW. Reply to: "Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma". J Hepatol 2018;69:751-2. [PMID: 29870761 DOI: 10.1016/j.jhep.2018.05.032] [Reference Citation Analysis]
78 Renzulli M, Tovoli F, Clemente A, Ierardi AM, Pettinari I, Peta G, Marasco G, Festi D, Piscaglia F, Cappabianca S, Carrafiello G, Golfieri R. Ablation for hepatocellular carcinoma: beyond the standard indications. Med Oncol 2020;37:23. [PMID: 32166482 DOI: 10.1007/s12032-020-01348-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
79 Sun J, Cheng N, Wang F. Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-10. [DOI: 10.1155/2022/1688460] [Reference Citation Analysis]
80 Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology 2022;75:1604-26. [PMID: 35253934 DOI: 10.1002/hep.32447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
81 Mathy RM, Tinoush P, da Florencia RD, Braun A, Ghamarnejad O, Radeleff B, Kauczor HU, Chang DH. Impact of needle positioning on ablation success of irreversible electroporation: a unicentric retrospective analysis. Sci Rep 2020;10:21902. [PMID: 33318515 DOI: 10.1038/s41598-020-78660-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
82 Chang H, Lee SH. Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis. Clin Exp Med 2022. [PMID: 35737170 DOI: 10.1007/s10238-022-00842-z] [Reference Citation Analysis]
83 Lee GC, Ferrone CR, Vagefi PA, Uppot RN, Tanabe KK, Lillemoe KD, Blaszkowsky LS, Qadan M. Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. Am J Surg 2019;218:157-63. [PMID: 30635211 DOI: 10.1016/j.amjsurg.2018.12.067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
84 Qu C, Li XQ, Li C, Xia F, Feng K, Ma K. The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma with Cirrhosis. J Invest Surg 2021;:1-8. [PMID: 34085878 DOI: 10.1080/08941939.2021.1931575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Yeo I, Kim GA, Kim H, Lee JH, Sohn A, Gwak GY, Lee JH, Lim YS, Kim Y. Proteome Multimarker Panel With Multiple Reaction Monitoring-Mass Spectrometry for Early Detection of Hepatocellular Carcinoma. Hepatol Commun 2020;4:753-68. [PMID: 32363324 DOI: 10.1002/hep4.1500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Long H, Xie X, Huang G, Huang T, Xie X, Liu B. Prognostic Role of Albumin-Bilirubin Grade in Hepatocellular Carcinoma After Ultrasound-guided Percutaneous Radiofrequency Ablation: A Single-center Experience Over a Decade. Surg Laparosc Endosc Percutan Tech 2022;32:350-6. [PMID: 35297807 DOI: 10.1097/SLE.0000000000001049] [Reference Citation Analysis]
87 Conci S, D'Onofrio M, Bianco A, Campagnaro T, Martone E, De Bellis M, Longo C, Dedoni S, Vittoria D'Addetta M, Ciangherotti A, Pedrazzani C, Dalbeni A, Campagnola P, Mansueto G, Guglielmi A, Ruzzenente A. Ablation Difficulty Score: Proposal of a new tool to predict success rate of percutaneous ablation for hepatocarcinoma. Eur J Radiol 2022;146:110097. [PMID: 34896959 DOI: 10.1016/j.ejrad.2021.110097] [Reference Citation Analysis]
88 Xie L, Cao F, Qi H, Song Z, Shen L, Chen S, Hu Y, Chen C, Fan W. Efficacy and safety of CT-guided percutaneous thermal ablation for hepatocellular carcinoma adjacent to the second porta hepatis. International Journal of Hyperthermia 2019;36:1121-7. [DOI: 10.1080/02656736.2019.1684575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Hermida M, Preel A, Assenat E, Piron L, Cassinotto C, Ursic-Bedoya J, Guillot C, Herrero A, Panaro F, Pageaux GP, Guiu B. Small Steatotic HCC: A Radiological Variant Associated With Improved Outcome After Ablation. Hepatol Commun 2021;5:689-700. [PMID: 33860126 DOI: 10.1002/hep4.1661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Liang Y, Chang C, Sheu M, Lin S, Chung C, Teng C, Suk F. The Antihistamine Deptropine Induces Hepatoma Cell Death through Blocking Autophagosome-Lysosome Fusion. Cancers 2020;12:1610. [DOI: 10.3390/cancers12061610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
91 Li W, Liu J, Huang TY, Zhong X, Yang DP, Xie XH, Liu DH, Xie XY, Zhuang BW. Lesion outline and thermal field distribution of ablative in vitro experiments in myocardia: comparison of radiofrequency and laser ablation. BMC Cardiovasc Disord 2020;20:454. [PMID: 33081697 DOI: 10.1186/s12872-020-01735-3] [Reference Citation Analysis]
92 Wang X, Yang Z, Meng Z, Sun S. Transforming Commercial Copper Sulfide into Injectable Hydrogels for Local Photothermal Therapy. Gels 2022;8:319. [DOI: 10.3390/gels8050319] [Reference Citation Analysis]
93 Tu Q, You X, He J, Hu X, Xie C, Xu G. Circular RNA Circ-0003006 Promotes Hepatocellular Carcinoma Proliferation and Metastasis Through Sponging miR-542-3p and Regulating HIF-1A. Cancer Manag Res 2021;13:7859-70. [PMID: 34675680 DOI: 10.2147/CMAR.S315894] [Reference Citation Analysis]
94 Rochigneux P, Nault JC, Mallet F, Chretien AS, Barget N, Garcia AJ, Del Pozo L, Bourcier V, Blaise L, Grando-Lemaire V, N'Kontchou G, Nahon P, Seror O, Ziol M, Ganne-Carrié N, Olive D. Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. Oncoimmunology 2019;8:1615818. [PMID: 31413924 DOI: 10.1080/2162402X.2019.1615818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
95 Inoue T, Yoneda M. Updated evidence on the clinical impact of endoscopic radiofrequency ablation in the treatment of malignant biliary obstruction. Dig Endosc 2021. [PMID: 34107114 DOI: 10.1111/den.14059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Lee SK, Chung DJ, Cho SH. A Real-World Comparative Study of Microwave and Radiofrequency Ablation in Treatment-Naïve and Recurrent Hepatocellular Carcinoma. J Clin Med 2022;11:302. [PMID: 35053997 DOI: 10.3390/jcm11020302] [Reference Citation Analysis]
97 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
98 Liu W, Zou R, Wang C, Qiu J, Shen J, Liao Y, Yang Z, Zhang Y, Wang Y, Yuan Y, Li K, Zuo D, He W, Zheng Y, Li B, Yuan Y. Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis. Ther Adv Med Oncol 2019;11:1758835919874652. [PMID: 31588210 DOI: 10.1177/1758835919874652] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
99 Lachenmayer A, Tinguely P, Maurer MH, Frehner L, Knöpfli M, Peterhans M, Weber S, Dufour J, Candinas D, Banz V. Stereotactic image‐guided microwave ablation of hepatocellular carcinoma using a computer‐assisted navigation system. Liver Int 2019;39:1975-85. [DOI: 10.1111/liv.14187] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
100 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
101 Zheng H, Xu C, Wang X, Li J, Zhao X, Qi J, Feng Y, Zhu Q. Microwave ablation shows similar survival outcomes compared with surgical resection for hepatocellular carcinoma between 3 and 5 cm. Int J Hyperthermia 2020;37:1345-53. [PMID: 33289415 DOI: 10.1080/02656736.2020.1849825] [Reference Citation Analysis]
102 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
103 Lin XC, Yan Y, Lin L, Lin QF, Chen J, Lin ZY, Chen J. Magnetic resonance-guided thermal ablation for small liver malignant tumor located on segment II or IVa abutting the heart: a retrospective cohort study. Int J Hyperthermia 2021;38:1359-65. [PMID: 34505553 DOI: 10.1080/02656736.2021.1976851] [Reference Citation Analysis]
104 Yeh WS, Chiang PL, Kee KM, Chang CD, Lu SN, Chen CH, Wang JH. Pre-sarcopenia is the prognostic factor of overall survival in early-stage hepatoma patients undergoing radiofrequency ablation. Medicine (Baltimore) 2020;99:e20455. [PMID: 32501992 DOI: 10.1097/MD.0000000000020455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Liu X, Zhang W, Xu Y, Xu X, Jiang Q, Ruan J, Wu Y, Zhou Y, Saw PE, Luo B. Targeting PI3Kγ/AKT Pathway Remodels LC3-Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation. Adv Sci (Weinh) 2022;9:e2102182. [PMID: 35037422 DOI: 10.1002/advs.202102182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Bai XM, Yang W. Radiofrequency ablation of hepatocellular carcinoma: Prognostic factors and recent advances. Shijie Huaren Xiaohua Zazhi 2021; 29(13): 677-683 [DOI: 10.11569/wcjd.v29.i13.677] [Reference Citation Analysis]
108 Chen H, Cheng H, Dai Q, Cheng Y, Zhang Y, Li D, Sun Y, Mao J, Ren K, Chu C, Liu G. A superstable homogeneous lipiodol-ICG formulation for locoregional hepatocellular carcinoma treatment.J Control Release. 2020;323:635-643. [PMID: 32302761 DOI: 10.1016/j.jconrel.2020.04.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
109 Yuan C, Wang Z, Gu D, Tian J, Zhao P, Wei J, Yang X, Hao X, Dong D, He N, Sun Y, Gao W, Feng J. Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram. Cancer Imaging. 2019;19:21. [PMID: 31027510 DOI: 10.1186/s40644-019-0207-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
110 Lyu N, Kong Y, Li X, Mu L, Deng H, Chen H, He M, Lai J, Li J, Tang H, Lin Y, Zhao M. Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. Front Oncol 2020;10:580241. [PMID: 33163408 DOI: 10.3389/fonc.2020.580241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Rennert J, Wiesinger I, Beyer LP, Schicho A, Stroszczynski C, Wiggermann P, Jung EM. Color coded perfusion analysis and microcirculation imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following thermal ablative techniques of primary and secondary liver malignancies. Clin Hemorheol Microcirc 2019;73:73-83. [PMID: 31561352 DOI: 10.3233/CH-199224] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
112 Han X, Dong J, Liu Z, Wu B, Tian Y, Tan H, Cheng W. Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study. International Journal of Hyperthermia 2020;37:1066-73. [DOI: 10.1080/02656736.2020.1817576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Zheng Q, Wei X, Rao J, Zhou C. Identification of key miRNAs in the progression of hepatocellular carcinoma using an integrated bioinformatics approach. PeerJ 2020;8:e9000. [PMID: 32411519 DOI: 10.7717/peerj.9000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Rogger TM, Michielan A, Sferrazza S, Pravadelli C, Moser L, Agugiaro F, Vettori G, Seligmann S, Merola E, Maida M, Ciarleglio FA, Brolese A, de Pretis G. Gastrointestinal tract injuries after thermal ablative therapies for hepatocellular carcinoma: A case report and review of the literature. World J Gastroenterol 2020; 26(35): 5375-5386 [PMID: 32994695 DOI: 10.3748/wjg.v26.i35.5375] [Reference Citation Analysis]
115 Fuentes D, Fahrenholtz SJ, Guo C, MacLellan CJ, Layman RR, Rivière B, Stafford RJ, Cressman E. Mathematical modeling of mass and energy transport for thermoembolization. Int J Hyperthermia 2020;37:356-65. [PMID: 32308071 DOI: 10.1080/02656736.2020.1749317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Li W, Ni CF. Current status of the combination therapy of transarterial chemoembolization and local ablation for hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:2268-75. [PMID: 31016345 DOI: 10.1007/s00261-019-01943-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
117 Liu J, Chen X, Zheng S. Immune response triggered by the ablation of hepatocellular carcinoma with nanosecond pulsed electric field. Front Med 2021;15:170-7. [PMID: 33185811 DOI: 10.1007/s11684-020-0747-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Soule E, Lamsal S, Lall C, Matteo J. Eye Opener to EtOH Ablation for Juxta-Cardiac Hepatocellular Carcinoma. Gastrointest Tumors 2019;5:109-16. [PMID: 30976582 DOI: 10.1159/000495135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
120 Kim CG, Lee HW, Choi HJ, Lee JI, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim HS, Kim KH, Choi SJ, Kim Y, Lee KS, Kim GM, Kim MD, Won JY, Lee DY, Kim BK. Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Med. 2019;8:5023-5032. [PMID: 31290618 DOI: 10.1002/cam4.2417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
121 Fu Y, Xi M, Pan Y, Chen J, Wang J, Liu S, Xu L, Zhou Z, Liu M, Chen M, Zhao L, Zhang Y. Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. J Oncol 2020;2020:4835653. [PMID: 32565803 DOI: 10.1155/2020/4835653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
122 Khokhlova TD, Schade GR, Wang YN, Buravkov SV, Chernikov VP, Simon JC, Starr F, Maxwell AD, Bailey MR, Kreider W, Khokhlova VA. Pilot in vivo studies on transcutaneous boiling histotripsy in porcine liver and kidney. Sci Rep 2019;9:20176. [PMID: 31882870 DOI: 10.1038/s41598-019-56658-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
123 Lim YS. Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. Korean J Gastroenterol 2021;78:284-8. [PMID: 34824186 DOI: 10.4166/kjg.2021.137] [Reference Citation Analysis]
124 Shen A, Liu M, Zheng D, Chen Q, Wu Z. Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2020;44:142-54. [PMID: 31303533 DOI: 10.1016/j.clinre.2019.06.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
125 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
126 Iezzi R, Bilhim T, Crocetti L, Peynircioglu B, Goldberg S, Bilbao JI, Sami A, Akhan O, Scalise P, Giuliante F, Pompili M, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. "Primum Non Nocere" in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications? Life (Basel) 2020;10:E180. [PMID: 32899925 DOI: 10.3390/life10090180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 Dumolard L, Ghelfi J, Roth G, Decaens T, Macek Jilkova Z. Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21. [PMID: 32575734 DOI: 10.3390/ijms21124398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
128 Zhao J, Li Q, Muktiali M, Ren B, Hu Y, Li D, Li Z, Li D, Xie Y, Tao M, Liang R. Effect of microwave ablation treatment of hepatic malignancies on serum cytokine levels. BMC Cancer 2020;20:812. [PMID: 32847533 DOI: 10.1186/s12885-020-07326-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Stankard M, Soule E, Matteo J. Inferior Vena Cava Syndrome as a Manifestation of Metastatic Carcinoid Tumor. Gastrointest Tumors 2021;8:138-43. [PMID: 34307313 DOI: 10.1159/000514113] [Reference Citation Analysis]
130 Bogdanovic A, Bulajic P, Masulovic D, Bidzic N, Zivanovic M, Galun D. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. Sci Rep 2021;11:4493. [PMID: 33627697 DOI: 10.1038/s41598-021-83868-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
131 Hermida M, Cassinotto C, Piron L, Aho-Glélé S, Guillot C, Schembri V, Allimant C, Jaber S, Pageaux GP, Assenat E, Guiu B. Multimodal Percutaneous Thermal Ablation of Small Hepatocellular Carcinoma: Predictive Factors of Recurrence and Survival in Western Patients. Cancers (Basel) 2020;12:E313. [PMID: 32013112 DOI: 10.3390/cancers12020313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
132 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Reference Citation Analysis]
133 Mohkam K, Dumont PN, Manichon AF, Jouvet JC, Boussel L, Merle P, Ducerf C, Lesurtel M, Rode A, Mabrut JY. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. J Hepatol 2018;68:1172-80. [PMID: 29410287 DOI: 10.1016/j.jhep.2018.01.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
134 Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma 2021;8:837-50. [PMID: 34350139 DOI: 10.2147/JHC.S308587] [Reference Citation Analysis]
135 Jia H, Yu F, Li B, Gao Z. Actin-binding protein Anillin promotes the progression of gastric cancer in vitro and in mice. J Clin Lab Anal 2021;35:e23635. [PMID: 33089886 DOI: 10.1002/jcla.23635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Hu B, Ding GY, Fu PY, Zhu XD, Ji Y, Shi GM, Shen YH, Cai JB, Yang Z, Zhou J, Fan J, Sun HC, Kuang M, Huang C. NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. J Hematol Oncol 2018;11:28. [PMID: 29482578 DOI: 10.1186/s13045-018-0573-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
137 Chen M, Zhang F, Song J, Weng Q, Li P, Li Q, Qian K, Ji H, Pietrini S, Ji J, Yang X. Image-Guided Peri-Tumoral Radiofrequency Hyperthermia-Enhanced Direct Chemo-Destruction of Hepatic Tumor Margins. Front Oncol 2021;11:593996. [PMID: 34235070 DOI: 10.3389/fonc.2021.593996] [Reference Citation Analysis]
138 Yang Y, Ye F, Xin Y, Wang Y, Li X, Feng D, Chen Y, Zhou X. Prognostic significance of controlling nutritional status score-based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation. J Gastrointest Oncol 2020;11:1024-39. [PMID: 33209495 DOI: 10.21037/jgo-20-225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
139 Jiang YQ, Cao SE, Cao S, Chen JN, Wang GY, Shi WQ, Deng YN, Cheng N, Ma K, Zeng KN, Yan XJ, Yang HZ, Huan WJ, Tang WM, Zheng Y, Shao CK, Wang J, Yang Y, Chen GH. Preoperative identification of microvascular invasion in hepatocellular carcinoma by XGBoost and deep learning.J Cancer Res Clin Oncol. 2021;147:821-833. [PMID: 32852634 DOI: 10.1007/s00432-020-03366-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
140 Zhang TQ, Huang SM, Gu YK, Gao F, Huang ZM, Jiang XY, Liu DX, Huang JH. Safety and effect on ablation size of hydrochloric acid-perfused radiofrequency ablation in animal livers. Int J Hyperthermia 2018;34:925-33. [PMID: 29457524 DOI: 10.1080/02656736.2018.1442588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
141 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
142 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]